title: Antiplatelet pathways development. Panel discussion.
authors.affiliation: Yale University, USA.
authors.forename: J
authors.initials: J
authors.lastname: Ballenger
authors.forename: J W
authors.initials: JW
authors.lastname: Olin
authors.forename: L M
authors.initials: LM
authors.lastname: Brass
authors.forename: B I
authors.initials: BI
authors.lastname: Orland
authors.forename: E
authors.initials: E
authors.lastname: Cannon
authors.forename: S J
authors.initials: SJ
authors.lastname: Rich
authors.forename: A
authors.initials: A
authors.lastname: Dresdale
authors.forename: C
authors.initials: C
authors.lastname: Stemple
authors.forename: K
authors.initials: K
authors.lastname: Moreo
authors.forename: R
authors.initials: R
authors.lastname: Zusman
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control; D019091:Critical Pathways; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control*; D014481:United States
chemical_list: D010975:Platelet Aggregation Inhibitors